Great Elm Capital Shareholders Are Encouraged to Reach out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Stock Information for Merrimack Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Merrimack Pharmaceuticals Inc.

Great Elm Capital Corp. Announces Fourth Quarter and Full Year 2025 Financial Results and New Executive Chairman of Board
Great Elm Capital Corp. ("GECC") Schedules Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
Great Elm Group Reports Fiscal 2026 Second Quarter Financial Results
Great Elm Capital Corp. Announces Third Quarter 2025 Financial Results
Great Elm Capital Corp. ("GECC") Schedules Third Quarter 2025 Earnings Release and Conference Call
Great Elm Capital Corp. ("GECC") Addresses Investor Questions with Respect to its First Brands Investments
Great Elm Capital Corp. Prices Public Offering of $50 Million of 7.75% Notes Due 2030
Great Elm Capital Corp. Announces Public Offering of Unsecured Notes

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.